Effect of an electronic nicotine delivery device (e-Cigarette) on smoking reduction and cessation: a prospective 6-month pilot study

Riccardo Polosa, Pasquale Caponnetto, Jaymin B Morjaria, Gabriella Papale, Davide Campagna, Cristina Russo, Riccardo Polosa, Pasquale Caponnetto, Jaymin B Morjaria, Gabriella Papale, Davide Campagna, Cristina Russo

Abstract

Background: Cigarette smoking is a tough addiction to break. Therefore, improved approaches to smoking cessation are necessary. The electronic-cigarette (e-Cigarette), a battery-powered electronic nicotine delivery device (ENDD) resembling a cigarette, may help smokers to remain abstinent during their quit attempt or to reduce cigarette consumption. Efficacy and safety of these devices in long-term smoking cessation and/or smoking reduction studies have never been investigated.

Methods: In this prospective proof-of-concept study we monitored possible modifications in smoking habits of 40 regular smokers (unwilling to quit) experimenting the 'Categoria' e-Cigarette with a focus on smoking reduction and smoking abstinence. Study participants were invited to attend a total of five study visits: at baseline, week-4, week-8, week-12 and week-24. Product use, number of cigarettes smoked, and exhaled carbon monoxide (eCO) levels were measured at each visit. Smoking reduction and abstinence rates were calculated. Adverse events and product preferences were also reviewed.

Results: Sustained 50% reduction in the number of cig/day at week-24 was shown in 13/40(32.5%) participants; their median of 25 cigs/day decreasing to 6 cigs/day (p < 0.001). Sustained 80% reduction was shown in 5/40(12.5%) participants; their median of 30 cigs/day decreasing to 3 cigs/day (p = 0.043). Sustained smoking abstinence at week-24 was observed in 9/40(22.5%) participants, with 6/9 still using the e-Cigarette by the end of the study. Combined sustained 50% reduction and smoking abstinence was shown in 22/40 (55%) participants, with an overall 88% fall in cigs/day. Mouth (20.6%) and throat (32.4%) irritation, and dry cough (32.4%) were common, but diminished substantially by week-24. Overall, 2 to 3 cartridges/day were used throughout the study. Participants' perception and acceptance of the product was good.

Conclusion: The use of e-Cigarette substantially decreased cigarette consumption without causing significant side effects in smokers not intending to quit (http://ClinicalTrials.gov number NCT01195597).

Figures

Figure 1
Figure 1
Structure of the 'Categoria' electronic-cigarette (e-Cigarette). The e-Cigarette is a battery-powered electronic nicotine delivery device (ENDD) resembling a cigarette designed for the purpose of providing inhaled doses of nicotine by way of a vaporized solution to the respiratory system. This device provides a flavor and physical sensation similar to that of inhaled tobacco smoke, while no smoke or combustion is actually involved in its operation. It is composed of the following key components: (1) the inhaler - also known as 'cartridge' (a disposable non-refillable plastic mouthpiece - resembling a tobacco cigarette's filter - which contains an absorbent material that is saturated with a liquid solution containing nicotine); (2) the atomizing device (the heating element that vaporizes the liquid in the mouthpiece and generates the mist with each puff); (3) the battery component (the body of the device - resembling a tobacco cigarette - which houses a lithium-ion re-chargeable battery to power the atomizer). The body of the device also houses an electronic airflow sensor to automatically activate the heating element upon inhalation and to light up a red LED indicator to signal activation of the device with each puff. Each pre-filled 'Original' cartridges used in this study contains nicotine (7.25 mg/cartridge) dissolved in propylene glycol (233.7 mg/cartridge) and vegetable glycerin (64.0 mg/cartridge) [details can be found at: http://www.liaf-onlus.org/public/allegati/categoria1b.pdf].
Figure 2
Figure 2
Number of patients recruited and flow of patients within the study. A total of 66 subjects with specifically predefined smoking criteria (smoking ≥ 15 cig/day for at least the past 10 years) responded to the advert; of these, 14 subjects were not included in the study because they spontaneously seek assistance with quitting (these were then invited to attend the local smoking cessation clinic, which offers standard support with cessation counselling and pharmacotherapy for nicotine dependence). The remaining 52 subjects consented to participate into the study; of these, 12 were not considered eligible because of the exclusion criteria (6 had a high blood pressure, 2 were older than 60; 2 had a diagnosis of major depression; 1 suffered from recent myocardial infarction; 1 had uncontrolled allergic asthma). In the end, 40 volunteers were included in the study and were issued with e-Cigarette kits loaded with nicotine cartridges. By the end of the study, a total of 13 subjects were lost to follow-up due to failure of attending their control visits. Overall 27 participants were available for analyses at the 24-week follow-up visit.
Figure 3
Figure 3
Changes in the mean (± SD) cigarette use for each study subgroups throughout the study.
Figure 4
Figure 4
Changes in the mean (± SD) eCO levels for each study subgroups throughout the study.
Figure 5
Figure 5
Changes in the mean (± SD) cartridge use for each study subgroups throughout the study.

References

    1. Tobacco or Health:a Global Status Report. Geneva; 1997.
    1. Doll R, Peto R, Boreham J, Sutherland I. Mortality in relation to smoking: 50 years' observations on male British doctors. BMJ. 2004;328(7455):1519. doi: 10.1136/.
    1. Boyle P, Gray N, Henningfield J, Seffrin J, Zatonski W. Tobacco and Public Health: Science and Policy. Oxford: Oxford University Press; 2004.
    1. Services UDoHaH: USA, US Department of Health and Human Services, Public Health Service, Centers for Disease Control, Center for Chronic Disease Prevention and Health Promotion, Office on Smoking and Health, editor. The health benefits of smoking cessation. 1990.
    1. Lightwood JM, Glantz SA. Short-term economic and health benefits of smoking cessation: myocardial infarction and stroke. Circulation. 1997;96(4):1089–1096.
    1. Fiore MC, Jaen CR, Baker TB, Bailey WC, Benowitz NL, Curry SJ, Dorfman SF, In: Treating tobacco use and dependence. Clinical practice guidelines 2008 Update. Services UDoHaH. Rockville, MD: Public Health Service, editor. 2008.
    1. Hughes JR, Keely J, Naud S. Shape of the relapse curve and long-term abstinence among untreated smokers. Addiction. 2004;99(1):29–38. doi: 10.1111/j.1360-0443.2004.00540.x.
    1. Casella G, Caponnetto P, Polosa R. Therapeutic advances in the treatment of nicotine addiction: Present and Future. Ther Adv Chronic Dis. 2010;1(3):95–106. doi: 10.1177/2040622310374896.
    1. Hon L. In: A non-smokable electronic spray cigarette (CA 2518174) {Patent notice} Record CPO, editor. Vol. 133. p. 2005.
    1. Zezima K. Cigarettes without smoke or regulation. New York Times. New York; 2009.
    1. Etter JF. Electronic cigarettes: a survey of users. Vol. 10. BMC Public Health; 2010. p. 231.
    1. Vansickel AR, Cobb CO, Weaver MF, Eissenberg TE. A clinical laboratory model for evaluating the acute effects of electronic "cigarettes": nicotine delivery profile and cardiovascular and subjective effects. Cancer Epidemiol Biomarkers Prev. 2010;19(8):1945–1953. doi: 10.1158/1055-9965.EPI-10-0288.
    1. Fagerstrom KO, Schneider NG. Measuring nicotine dependence: a review of the Fagerstrom Tolerance Questionnaire. J Behav Med. 1989;12(2):159–182. doi: 10.1007/BF00846549.
    1. Beck A, Ward C, Mendelson M, Mock J, Erbaugh J. Manual for the Beck Depression Inventory. New York Harcourt Brace Jovanovich; 1987.
    1. Bolliger CT, Zellweger JP, Danielsson T, van Biljon X, Robidou A, Westin A, Perruchoud AP, Sawe U. Smoking reduction with oral nicotine inhalers: double blind, randomised clinical trial of efficacy and safety. BMJ. 2000;321(7257):329–333. doi: 10.1136/bmj.321.7257.329.
    1. Polosa R, Russo C, Di Maria A, Arcidiacono G, Piccillo G. Smoking cessation and reduction through e-mail counselling. Respir Med. 2008;102(4):632. doi: 10.1016/j.rmed.2007.12.024.
    1. Smith SS, McCarthy DE, Japuntich SJ, Christiansen B, Piper ME, Jorenby DE, Fraser DL, Fiore MC, Baker TB, Jackson TC. Comparative effectiveness of 5 smoking cessation pharmacotherapies in primary care clinics. Arch Intern Med. 2009;169(22):2148–2155. doi: 10.1001/archinternmed.2009.426.
    1. Laurier E, McKie L, Goodwin N. Daily and life-course contexts of smoking. Sociol Health llln. 2000;22:289–309. doi: 10.1111/1467-9566.00205.
    1. Jarvis MJ. Why people smoke. BMJ. 2004;328(7434):277–279. doi: 10.1136/bmj.328.7434.277.
    1. Bullen C, McRobbie H, Thornley S, Glover M, Lin R, Laugesen M. Effect of an electronic nicotine delivery device (e cigarette) on desire to smoke and withdrawal, user preferences and nicotine delivery: randomised cross-over trial. Tob Control. 2010;19(2):98–103. doi: 10.1136/tc.2009.031567.
    1. Caponnetto P, Cibella F, Mancuso S, Campagna D, Arcidiacono G, Polosa R. Effect of a nicotine free inhalator as part of a smoking cessation program. Eur Respir J. 2011 May 12. [Epub ahead of Print].
    1. Fagerstrom KO, Hughes JR, Rasmussen T, Callas PW. Randomised trial investigating effect of a novel nicotine delivery device (Eclipse) and a nicotine oral inhaler on smoking behaviour, nicotine and carbon monoxide exposure, and motivation to quit. Tob Control. 2000;9(3):327–333. doi: 10.1136/tc.9.3.327.
    1. Wieslander G, Norback D, Lindgren T. Experimental exposure to propylene glycol mist in aviation emergency training: acute ocular and respiratory effects. Occup Environ Med. 2001;58(10):649–655. doi: 10.1136/oem.58.10.649.
    1. Varughese S, Teschke K, Brauer M, Chow Y, van Netten C, Kennedy SM. Effects of theatrical smokes and fogs on respiratory health in the entertainment industry. Am J Ind Med. 2005;47(5):411–418. doi: 10.1002/ajim.20151.
    1. McNeill A. Harm reduction. BMJ. 2004;328(7444):885–887. doi: 10.1136/bmj.328.7444.885.
    1. Bolliger CT, Zellweger JP, Danielsson T, van Biljon X, Robidou A, Westin A, Perruchoud AP, Sawe U. Influence of long-term smoking reduction on health risk markers and quality of life. Nicotine Tob Res. 2002;4(4):433–439. doi: 10.1080/1462220021000018380.
    1. Hatsukami DK, Kotlyar M, Allen S, Jensen J, Li S, Le C, Murphy S. Effects of cigarette reduction on cardiovascular risk factors and subjective measures. Chest. 2005;128(4):2528–2537. doi: 10.1378/chest.128.4.2528.
    1. Godtfredsen NS, Prescott E, Osler M. Effect of smoking reduction on lung cancer risk. JAMA. 2005;294(12):1505–1510. doi: 10.1001/jama.294.12.1505.
    1. Hughes JR, Carpenter MJ. The feasibility of smoking reduction: an update. Addiction. 2005;100(8):1074–1089. doi: 10.1111/j.1360-0443.2005.01174.x.
    1. Wennike P, Danielsson T, Landfeldt B, Westin A, Tonnesen P. Smoking reduction promotes smoking cessation: results from a double blind, randomized, placebo-controlled trial of nicotine gum with 2-year follow-up. Addiction. 2003;98(10):1395–1402. doi: 10.1046/j.1360-0443.2003.00489.x.
    1. Rennard SI, Glover ED, Leischow S, Daughton DM, Glover PN, Muramoto M, Franzon M, Danielsson T, Landfeldt B, Westin A. Efficacy of the nicotine inhaler in smoking reduction: A double-blind, randomized trial. Nicotine Tob Res. 2006;8(4):555–564. doi: 10.1080/14622200600789916.
    1. Walker N, Bullen C, McRobbie H. Reduced-nicotine content cigarettes: Is there potential to aid smoking cessation? Nicotine Tob Res. 2009;11(11):1274–1279. doi: 10.1093/ntr/ntp147.
    1. Polosa R, Benowitz NL. Treatment of nicotine addiction: present therapeutic options and pipeline developments. Trends Pharmacol Sci. 2011;32(5):281–9. doi: 10.1016/j.tips.2010.12.008.

Source: PubMed

Sponzoři a spolupracovníci

Zdravotní podmínky

Drogové intervence

3
Předplatit